SLC22A1 and leukemia: The degree of OCT1 expression has been suggested to be a useful biomarker to predict the success of imatinib-based therapy in leukemia patients, and, furthermore, leukemia patients who had higher OCT1 expression levels showed a better response to the drug [47, 48].